Henning Clausen

Dr. Henning Clausen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HCHenning Clausen
Henning Clausen
EFElin Friberg
Elin Friberg
KLKatarina Lannering
Katarina Lannering
AKAki Koivu
Aki Koivu
MSMikko Sairanen
Mikko Sairanen
PLPetru Liuba
Petru Liuba
Congenital heart disease (CHD) is the most common organ malformation in humans, affecting approximately 1 of 125 newborns.1 Critical CHD, defined as cases dependent on patency of the arterial duct for survival after birth, occurs in approximately 1 of 500 newborns and requires urgent medical attention to prevent circulatory collapse and early surgical management to stabilize the circulation.2-4 Such critical cases, along with other severe types of CHD that require cardiac surgery during infancy to prevent heart failure and mortality, can be considered high-risk CHD. There is a global need to improve early diagnosis of such high-risk cases while overcoming inequalities in CHD care provision to achieve optimal outcomes.4 Identifying such cases can be partially achieved by prenatal maternal ultrasound screening with detection in approximately half of cases, which in turn provides time for parental counselling, planning, and postnatal stabilization prior to surgery, even though these cases may often represent the most complex CHD forms.5-7 The remainder of cases will rely on timely, postnatal diagnoses to minimize morbidity and mortality using clinical examinations or additional newborn pulse oximetry screening, although the latter continues to have modest sensitivity with diagnoses, such as aortic coarctation, that represent significant challenges.8,9 We set out to develop quantitative DBS assays for the amino-terminal prohormone of brain natriuretic peptide (NT-proBNP) and interleukin 1 receptor-like 1 protein (IL-1 RL1; formerly known as soluble ST2) and evaluated these among a Swedish cohort of newborns. Biomarkers were selected based on published scientific data that have suggested a strong relationship between heart failure and elevated blood biomarker levels in various age groups and types of cardiac diseases, both in adults and children.10-16 To address the need for timely and efficient detection of high-risk CHD in newborns, we hypothesized that the cardiovascular biomarkers NT-proBNP and IL-1 RL1 could aid this process if analyzed using minimal amounts of dried blood spot (DBS) samples, as commonly used in newborn screening programs.

Verified
Journal Article
Open access
PDF file
HCHenning Clausen
Henning Clausen
EFElin Friberg
Elin Friberg
MSMikko Sairanen
Mikko Sairanen
PSPia Sjöberg
Pia Sjöberg
PLPetru Liuba
Petru Liuba
Soluble growth stimulation protein form of interleukin-1 receptor-like 1 (ST2) may signal myocardial stress, and elevated ST2 blood levels are associated with adverse outcomes in adult heart disease. Data on ST2 in children with congenital heart disease (CHD) is limited. This study explored ST2 in newborns and older children with atrial septal defect (ASD), as this represents a common CHD type that remains clinically challenging to recognize in childhood with slowly evolving symptoms. A case–control study was carried out in newborn ASD cases versus controls measuring ST2 on dried blood spot samples and additionally in pediatric ASD cases versus controls on venous blood together with cardiac magnetic resonance before and after treatment. ST2 was higher in newborns with ASD (n = 19) compared to controls (n = 93); (p < 0.01). Receiver operating characteristics to diagnose newborn ASD by ST2 showed an area under the curve of 0.848. Levels of ST2 decreased in pediatric ASD (n = 16) after treatment (p = 0.014). Lower left ventricular ejection fraction correlated with higher ST2 levels before (r = −0.348) and after treatment (r = −0.497). Elevated ST2 in newborns may aid early ASD diagnosis. Levels of ST2 in pediatric ASD decrease after treatment, and higher levels are associated with lower left ventricular ejection fraction, warranting further study.